Valganciclovir: A New Oral Alternative for Cytomegalovirus Retinitis in Human Immunodeficiency Virus-Seropositive Individuals
- 1 September 2002
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 22 (9) , 1124-1128
- https://doi.org/10.1592/phco.22.13.1124.33527
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus RetinitisNew England Journal of Medicine, 2002
- ValganciclovirDrugs, 2001
- Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant RecipientsAntimicrobial Agents and Chemotherapy, 2000
- Single‐Dose Pharmacokinetics of Valganciclovir in HIV‐ and CMV‐Seropositive SubjectsThe Journal of Clinical Pharmacology, 1999
- Pharmacokinetics of Valganciclovir and Ganciclovir Following Multiple Oral Dosages of Valganciclovir in HIV- and CMV-Seropositive VolunteersClinical Pharmacokinetics, 1999